Ruta Rao, MD

Experts discuss the evolving landscape of breast cancer treatment, emphasizing the importance of ctDNA testing for personalized therapy decisions.

Experts discuss balancing efficacy and quality of life in SERD therapies, highlighting unique toxicities and the importance of patient education.

Experts discuss the low incidence of ILD in T-DXd trials and the importance of vigilant screening in neoadjuvant settings for better patient outcomes.

Early detection of ESR1 mutations in breast cancer enhances treatment strategies, potentially improving patient outcomes and quality of life.

Clinicians explore the differences between EMERALD and EMBER3 trials, focusing on patient characteristics, treatment efficacy, and future therapy roles.

New trials reveal T-DXd's effectiveness in high-risk HER2-positive breast cancer, showing significant improvements in treatment response rates.

Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.

Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.

Experts discuss the evolving strategies in HER2-positive breast cancer treatment, focusing on maintenance therapies and patient-specific approaches.

Experts discuss the impact of biomarkers and treatment duration on decision-making for CDK4/6 inhibitors in breast cancer adjuvant therapy.

Discover effective strategies for managing toxicities in patients using CDK4/6 inhibitors, ensuring adherence and optimal treatment outcomes.

Experts discuss evolving strategies and unmet needs in HER2-positive breast cancer treatment, focusing on emerging therapies and clinical trial insights.

Clinicians explore barriers to adjuvant CDK4/6-inhibitor therapy, emphasizing education and streamlined communication to improve patient outcomes.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

Segment 1 establishes the current treatment landscape for HER2-positive metastatic breast cancer (mBC) and highlights key unmet clinical needs.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

CDK4/6 Inhibition in HR-Positive Breast Cancer: Evolving Standards in Early and Metastatic Care